Rare Pediatrics News
Disease Profile
Oncogenic osteomalacia
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
Unknown
Age of onset
All ages
ICD-10
M83.8
Inheritance
Autosomal dominant A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease.
Autosomal recessive Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype.
X-linked
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
Mitochondrial or multigenic Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Not applicable
Other names (AKA)
Tumor-induced osteomalacia; Oncogenic hypophosphatemic osteomalacia; TIO
Summary
Oncogenic osteomalacia is characterized by the development of a
The exact reason that the tumors associated with oncogenic osteomalacia develop is not known. The disease is diagnosed when a person experiences clinical features such as bone weakening and hyperphosphaturia and a tumor is found by
Symptoms
The majority of
Cause
Exactly what causes the development of the tumors associated with tumor-induced osteomalacia is unknown. It is most likely that these tumors develop by chance.[4]
Diagnosis
When oncogenic osteomalacia is suspected, the
Treatment
Typically, the tumors associated with oncogenic osteomalacia are not malignant, meaning that they are unlikely to spread to other parts of the body. Therefore,
When the tumor cannot be located or cannot be removed surgically, medications are available that can help increase the levels of phosphate and vitamin D in the blood. This is possible by taking phosphate supplements and calcitriol, which helps increase levels of vitamin D.[4]
Learn more
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
Where to Start
- MedlinePlus was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.
In-Depth Information
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Oncogenic osteomalacia. Click on the link to view a sample search on this topic.
References
- Kumar K and Halkar RK. Tumor-Induced Osteomalacia (TIO) (also Known as Oncogenic osteomalacia). Applied Radiology. 2008; 37(1):9-24. https://www.medscape.com/viewarticle/570120.
- Chong WH, Molinolo AA, Chen CC, and Collins MT. Tumor-induced osteomalacia. Endocrine-Related Cancer. June 2011; 18(3):R53-R77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433741/.
- Zuo Q, Wang H, Li W, Niu X, Huang Y, Chen J, You Y, Liu B, Cui A, and Deng W. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskeletal Disorders. 2017; 18:403. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609032/.
- Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D, Butenas P, and Kacerguis T. Tumor-induced osteomalacia: a literature review and a case report. World Journal of Surgical Oncology. 2016; 14:4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705745/.
- Lee JY, Park HS, Han S, Lim JK, Hong N, Park S, and Rhee Y. Localization of Oncogenic osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23. Yonsei Medical Journal. September 1, 2017; 58(5):981-987. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552653/.
- Chokyu I, Ishibashi K, Goto T, and Ohata K. Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report. Journal of Medical Case Reports. 2012; 6:181. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514377/.
Rare Pediatrics News